ATF6 Pathway Screening via Fluorescent Peptide Domain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating endoplasmic reticulum stress lack a system for real-time, sensitive assessment of ATF6 pathway activation, hindering the identification of endoplasmic reticulum stressors and inhibitors, and antidiabetic drug candidates.
Innovation Solution
A method utilizing a polynucleotide encoding a nonfluorescent peptide domain from a fluorescent protein and the ATF6 protein domain, allowing for real-time evaluation of ATF6 pathway activation in viable cells through fluorescence intensity measurement, enabling the screening of endoplasmic reticulum stressors, inhibitors, and antidiabetic drug candidates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing evaluation systems for endoplasmic reticulum stress are used, then general stress assessment is possible, but real-time sensitive evaluation of ATF6 pathway activation is not achievable
Solution Approach 1:
The patent employs fluorescence emission as a detectable signal to monitor ATF6 pathway activation. The fluorescent protein domain undergoes conformational changes upon ATF6 activation, producing fluorescence that can be quantified in real-time, thereby transforming an invisible biochemical process into a measurable optical signal that enables sensitive detection.
Solution Approach 2:
The patent introduces a fluorescent protein domain as an intermediary molecule that binds to or interacts with ATF6. This intermediary converts the biochemical activation state of ATF6 into a detectable fluorescence signal, serving as a mediator between the target protein and the detection system.
2Adaptability or versatility
If comprehensive screening of endoplasmic reticulum stressors is conducted, then identification of stressors and inhibitors is improved, but the complexity of the evaluation system increases
Solution Approach 1:
The patent creates a universal evaluation system based on the ATF6 pathway that can screen for multiple types of substances including endoplasmic reticulum stressors, inhibitors, and antidiabetic drug candidates. The same fluorescent-based assay platform can detect activation or inhibition effects of different substance classes, providing multi-functional screening capability without requiring separate assays for each substance type.
3Duration of action of moving object
If real-time evaluation of viable cells is implemented, then dynamic cellular response is captured, but measurement sensitivity and accuracy requirements increase
Solution Approach 1:
The patent replaces complex mechanical or biochemical assay systems with optical measurement techniques. By using fluorescence emission as the readout, the system substitutes intricate cellular analysis with simpler, more precise optical detection that can be performed in real-time on viable cells, improving both temporal resolution and measurement accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables sensitive and accurate real-time evaluation of ATF6 pathway activation, facilitating the identification of substances that activate or inhibit the ATF6 pathway, and aiding in the discovery of antidiabetic drug candidates by simultaneously assessing all three major endoplasmic reticulum stress response pathways.
Implementation Method 1
a nonfluorescent peptide domain 1 derived from a fluorescent protein... allowing for real-time evaluation of ATF6 pathway activation in viable cells through fluorescence intensity measurement
Data Source
AI summary
A system for evaluating activation of the pathway mediated by ATF6. More specifically, a method for screening an endoplasmic reticulum stressor, as well as a method for screening a substance for suppressing an endoplasmic reticulum stress induced by the activation of the pathway mediated by ATF6, and a method for screening an antidiabetic drug candidate. A method for real-time evaluation of activation of the pathway mediated by ATF6 in viable cells. The method uses a polynucleotide encoding a nonfluorescent peptide domain derived from a fluorescent protein and an ATF6 protein domain.